OBM Business Summary

Original BioMedicals Co., Ltd. (OBM) is a clinical-stage biotechnology firm specializing in the development of non-new chemical entity (non-NCE) drugs through proprietary drug delivery platforms. The company generates revenue primarily through strategic authorization cooperation (licensing), research and development service fees, and the commercialization of reformulated therapeutics. Its core business segments leverage patented Nanocomposite Micelle Technology and Triggered Controlled Release Technology to enhance the safety and efficacy of established active ingredients. OBM’s high-density pipeline includes OBM-B01 for cyanide detoxification, OBM-A01 for radiation injury prevention, and OBM-CL for severe antibiotic infections. Within the Taiwan biotech ecosystem, OBM competes directly with drug delivery and reformulation specialists such as PharmaEngine (4162.TW), Taiwan Liposome Company (TLC), and Orient EuroPharma (4120.TW), positioning itself as a niche leader in optimizing half-life and reducing toxicity for critical care and oncology applications. The company’s leadership is anchored by Chairman Kun-Da Wu and Chief Executive Officer Dr. Cliff C. Wang, Ph.D., who has directed OBM’s strategic and clinical operations since 2016. Dr. Wang, who also serves as the Chief Research Officer, possesses a deep pedigree in pharmaceutical R&D and has been instrumental in advancing the firm’s micelle-based delivery assets from inception in 2011 through its listing on the Taipei Exchange. OBM is backed by notable institutional investors, including Diamond Biofund and Maxpro Ventures, which provide the capital necessary for its dual-track strategy of domestic commercialization and international licensing. The board of directors remains focused on leveraging its technological platforms to transform established chemistries into high-value clinical therapies, maintaining a lean operational structure with approximately 23 specialized employees as of March 2026.